A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19

Int J Mol Sci. 2023 Mar 28;24(7):6369. doi: 10.3390/ijms24076369.

Abstract

Influenza virus and coronavirus, two kinds of pathogens that exist widely in nature, are common emerging pathogens that cause respiratory tract infections in humans. In December 2019, a novel coronavirus SARS-CoV-2 emerged, causing a severe respiratory infection named COVID-19 in humans, and raising a global pandemic which has persisted in the world for almost three years. Influenza virus, a seasonally circulating respiratory pathogen, has caused four global pandemics in humans since 1918 by the emergence of novel variants. Studies have shown that there are certain similarities in transmission mode and pathogenesis between influenza and COVID-19, and vaccination and antiviral drugs are considered to have positive roles as well as several limitations in the prevention and control of both diseases. Comparative understandings would be helpful to the prevention and control of these diseases. Here, we review the study progress in the etiology, pathogenesis, vaccine and antiviral drug development for the two diseases.

Keywords: SARS-CoV-2; antiviral drug; etiology; influenza virus; pathogenesis; spread; vaccines.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Drug Development
  • Humans
  • Influenza Vaccines*
  • Influenza, Human* / drug therapy
  • Influenza, Human* / prevention & control
  • Respiratory Tract Infections* / drug therapy
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Influenza Vaccines